Expression of miR-9a-5p in cirrhosis patients with recurrent portal hypertension after treatment

Abstract

Background. MicroRNA (miR) influences the biological activities of cirrhotic patients with recurrent portal hypertension.Objectives. The current study was designed to investigate risk factors related to the survival of cirrhosis patients and assessed the possibility of using miR-9a-5p predictability to prevent post-treatment portal hypertension. Materials and methods.Patients with portal hypertension due to liver cirrhosis treated from January 2015 to September 2016 were included in this study. Patients without relapse after treatment were selected as the success group while patients with relapse after treatment were selected as the recurrence group. Serum samples from healthy people were also collected. The blood indexes of the 2 groups of patients before and after treatment were compared and the miR-9a-5p serum level in each group was determined. The Kaplan-Meier method was applied to analyze three-year survival, Cox univariate regression was used to analyze the risk factors for recurrence of cirrhotic portal hypertension, and the receiver operating characteristic curve (ROC) was used to evaluate the diagnostic value of serum miR-9a-5p, total bilirubin (TBIL) and platelet (PLT) levels in patients with recurrence.Results. The miR-9a-5p level in the recurrence group was higher than that in the success group after treatment. In patients with recurrence, the miR-9a-5p level was negatively correlated with red blood cell count, TBIL, white blood cell count, and PLT count, and positively correlated with albumin. The miR-9a-5p, TBIL and PLT are potential markers of recurrent portal hypertension in liver cirrhosis. The miR-9a-5p had the highest area under the curve (AUC) value in patients with relapse. Conclusions.The miR-9a-5p is a risk factor for the recurrence of cirrhotic portal hypertension after treatment. It may be used as a marker of recurrence, and so has potential clinical value for the diagnosis and treatment of recurrent portal hypertension.

Therapeutic aspect of microRNA inhibition in various types of hypertension and hypertensive complications

“…Some of the key considerations that are designed for RNAi therapeutic as new drug are it must address an unmet medical need; the drug must have the good pharmacokinetic feature and also the drug must be safer and/or more effective than the existing standard of care. MicroRNAs have the capacity to pleiotropically target hundreds or even thousands of genes and some of which have unique functions for distinct organs or cell types which are some of the common features (Nie et al, 2021). Accordingly, this raised the possibility that one miRNA candidate may have the power to control entire biological pathways that are disturbed by pathogens in a patient.…”